Glaukos Corporation
NYSE:GKOSMedical - Devices
-$0.18 today
- Market cap
- $13.80B
- Beta
- 0.81
- P/E (TTM)
- -39.0
- EPS (TTM)
- -$3.26
Volume 1.12M
Average 0.94M
GKOS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Glaukos CorporationNYSE: GKOS
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $51.3M rose 40.4% year over year, ahead of the +26.4% change in trailing-twelve-month research & development. Sequentially, it rose 16.2% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Research & development amounted to 29.7% of revenue in FY2025, down 5.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +40.4% holds above the trailing-twelve-month pace of +26.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 150.61M USD
- Year-over-year change
- +10.4%
- 4-year CAGR
- +10.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 150.61M | +10.4% |
| FY2024 | 2024-12-31 | 136.43M | -1.7% |
| FY2023 | 2023-12-31 | 138.77M | +12.6% |
| FY2022 | 2022-12-31 | 123.27M | +22.1% |
| FY2021 | 2021-12-31 | 101M | — |
Research & Development vs competitors
How GKOS compares with its peers on the latest reported figures
- GKOS's LTM Jun 2026 research & development of $177.17M is the 5th highest of the 9 companies compared; the peer median is $129.44M.
- Its year-over-year change of +26.4% is the 4th highest of 8, against a peer median of +12.5%.
- Research & development amounts to 28.9% of revenue for GKOS, versus a peer median of 16.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.44B | +51.4% | +12.1% | 13.1% | |
| LTM Jun 2026 | $404M | +12.5% | +6.5% | 7.6% | |
| LTM Mar 2026 | $234.61M | +45.4% | +64.5% | 3080.9% | |
| LTM Mar 2026 | $220.45M | +47.2% | +54.5% | 423.6% | |
| LTM Jun 2026 | $177.17M | +26.4% | +6.9% | 28.9% | |
| LTM Apr 2026 | $38.43M | -26.2% | +3.6% | 13.2% | |
| LTM Mar 2026 | $37.65M | +2.6% | +14.1% | 29.5% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $28.64M | — | — | — |
| LTM Mar 2026 | $12.72M | -28.5% | -13.9% | 16.0% | |
| Peer median (excluding GKOS) | $129.44M | +12.5% | +12.1% | 16.0% | |
Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 294.01M | 282.86M | 314.71M | 383.48M | 507.44M |
| Cost of Revenue | 66.63M | 68.98M | 75.58M | 94.03M | 114.23M |
| Gross Profit | 227.38M | 213.88M | 239.14M | 289.45M | 393.22M |
| Gross Margin | 77.3% | 75.6% | 76.0% | 75.5% | 77.5% |
| Research & Development | 101M | 123.27M | 138.77M | 136.43M | 150.61M |
| Selling, General & Admin | 179.26M | 192.93M | 224.07M | 262.85M | 329.34M |
| Operating Expenses | 260.26M | 296.2M | 367.84M | 411.82M | 479.95M |
| Depreciation & Amortization | 34.42M | 35.95M | 37.98M | 39.92M | 42.35M |
| EBITDA | (1.47M) | (48.76M) | (82.12M) | (95.64M) | (146.06M) |
| EBITDA Margin | -0.5% | -17.2% | -26.1% | -24.9% | -28.8% |
| Operating Income | (32.87M) | (82.31M) | (128.7M) | (122.37M) | (86.73M) |
| Operating Margin | -11.2% | -29.1% | -40.9% | -31.9% | -17.1% |
| Interest Income | 1.29M | 2.38M | 9.16M | 11.11M | 10.71M |
| Interest Expense | 13.37M | 13.72M | 13.63M | 10.04M | 4.64M |
| Other Income / Expenses | (16.4M) | (16.12M) | (5.03M) | (23.24M) | (106.31M) |
| Income Before Tax | (49.27M) | (98.43M) | (133.73M) | (145.6M) | (193.04M) |
| Pre-Tax Margin | -16.8% | -34.8% | -42.5% | -38.0% | -38.0% |
| Income Tax Expense | 326K | 766K | 934K | 771K | (5.35M) |
| Net Income | (49.59M) | (99.2M) | (134.66M) | (146.37M) | (187.69M) |
| Net Margin | -16.9% | -35.1% | -42.8% | -38.2% | -37.0% |
| EPS (Basic) | (1.07) | (2.09) | (2.78) | (2.77) | (3.28) |
| EPS (Diluted) | (1.07) | (2.09) | (2.78) | (2.77) | (3.28) |
| Weighted Avg Shares | 46.42M | 47.44M | 48.43M | 52.76M | 57.19M |
| Weighted Avg Shares (Diluted) | 46.42M | 47.44M | 48.43M | 52.76M | 57.19M |
Glaukos Corporation
NYSE:GKOS
Intrinsic Alpha fair value
Locked
Current Price
$233.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.